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Strengths and limitations of this study
 ► New information about the vasospastic angina pec-
toris patients in a western country.
 ► Unique registry data including all medical hospitals 
admissions with the diagnoses of vasospastic angi-
na from all hospitals treating acute cardiac patients 
in mainland Finland.
 ► Follow- up period of 11 years.
 ► Retrospective registry data and the diagnoses were 
made by different physicians.
 ► Coronary angiography was performed for 56% of 
the hospitalised patients limiting the accuracy of 
diagnoses.
AbStrACt
Objectives The occurrence and mortality of vasospastic 
angina pectoris (VAP) is largely unknown in western 
countries. Our objective was to clarify the occurrence, 
gender- distribution and mortality of VAP in Finland using a 
population- based hospital registry.
Methods We studied consecutive patients aged ≥18 years 
hospitalized with VAP as the primary cause of admission in 
Finland during 2004–2014. The data were collected from 
obligatory nationwide registries. During the study period 
1762 admissions were recorded.
results Majority of all VAP patients were male (59.7%) 
and mean age was 65.7±12.0 years. Annual admission 
rate for VAP was 2.29/100 000 person- years. Men were 
in higher risk for VAP than women (admission rate 
3.00/100 000 vs 1.68/100 000; RR 1.70; p<0.0001). 
Gender difference was not modified by age. Likelihood 
of VAP was highest in population aged 70–84 years. 
Admission rate for VAP decreased notably during the study 
period. One- year all- cause mortality was 8.0% and 3- year 
mortality was 15.5% (cardiac mortality 11.1%). Mortality 
was associated with increasing age, comorbidity burden 
and lack of detected coronary artery obstruction, but was 
similar between genders and during the study period.
Conclusions Men have higher risk for vasospastic angina 
caused admissions. Likelihood of vasospastic angina 
admission was highest in aged population. The 3- year all- 
cause mortality was 15.5%. Mortality was associated with 
increasing age, comorbidities and non- obstructive VAP 
diagnosis but was similar between genders.
IntrOduCtIOn
Vasospastic angina pectoris (VAP), or Prinz-
metal’s angina, originally described by Myron 
Prinzmetal et al,1 is defined as a sudden 
coronary vasoconstriction leading to exces-
sively reduced coronary blood flow causing 
myocardial ischaemia.2 The definite VAP 
diagnosis involves three considerations: (1) 
classical clinical manifestations of VAP (spon-
taneous nitrate responsive angina episodes), 
(2) documentation of myocardial ischaemia 
during spontaneous episodes, (3) demon-
stration of coronary artery spasm.3 4 Coro-
nary spasms occur mainly in large epicardial 
arteries but are known to occur also in coro-
nary microvasculature of the myocardium. 
Coronary spasms may be associated with scle-
rotic lesions in the arterial walls.3 5
The prevalence of VAP seems to vary in 
different patient populations, but it has 
been reported that about 40% of the angina 
patients have vasospastic angina3 and vaso-
spasm have been detected in a third of 
non-ST- elevation myocardial infarction (MI) 
patients.6 In more detail, VAP is well studied 
in Japanese population and appears more 
common in oriental countries in comparison 
to western countries. Also, there seem to be 
substantial differences between Caucasian 
and Japanese VAP patients3 7 with Japanese 
patients having more diffusely hypersensitive 
coronary arteries.8
The 3- year MI mortality of VAP patients has 
been reported to be 3% in Japanese popula-
tions and 2% in Korean population.3 9 10 Three- 
year MI mortality in western VAP population 
has been 11%.3 In Caucasian VAP patients 
with non- significant coronary obstructions, 
the all- cause mortality was 24% in a 140 
months follow- up and the deaths were mostly 
age- related.11
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Table 1 Patient characteristics of all hospital admission (n=1762)
Variable Total (n=1762) Male (n=1052) Female (n=710) P value*
Age (y, mean) 65.7±12.0 64.9±11.3 66.8±13.0 0.002
CCI score       0.178
  0 975 (55.3%) 576 (54.8%) 399 (56.2%)
  1 415 (23.6%) 246 (23.4%) 169 (23.8%)
  2 224 (12.7%) 131 (12.5%) 93 (13.1%)
  ≥3 148 (8.4%) 99 (9.4%) 49 (6.9%)
Coronary angiography performed† 992 (56.3%) 614 (58.4%) 378 (53.2%) 0.033
Angiographical finding       <0.0001
  No obstruction 793 (45.0%) 440 (41.8%) 353 (49.7%)
  Obstruction 498 (28.3%) 346 (32.9%) 152 (21.4%)
  NAS 471 (26.7%) 266 (25.3%) 205 (28.9%)
*Between genders.
†During vasospastic angina pectoris admission.
CCI, Charlson comorbidity index; NAS, Not otherwise specified.
Several VAP patient series and registries originating mainly 
from oriental populations have been reported whereas to 
our knowledge the occurrence of VAP at population level 
in western countries is less well studied. We set out to clarify 
the occurrence, gender- distribution and mortality of VAP 
in Finland using a population- based hospital registry.
MethOdS
Study population
We studied patients aged ≥18 years hospitalised with VAP 
(ICD-10 code I20.1X) as the primary cause of admission. 
Data of all medical hospitals admissions from all hospitals 
treating acute cardiac patients in mainland Finland between 
1 January 2004 and 31 December 2014 were retrospectively 
collected from the Care Register for Health Care, a nation-
wide database containing all hospital discharge data from 
all admissions in Finland and maintained by the Finnish 
National Institute for Health and Welfare. VAP types were 
classified based on ICD-10 coding and the performed oper-
ations were identified based on operational codes (Nordic 
Classification of Surgical Procedures).
Finnish hospital system consists of three main levels: 
university hospitals (n=5) representing the highest level 
of hierarchy, followed by central hospitals (n=16) with 
coronary catherisation laboratories and intensive care 
units, and then several smaller regional hospitals. Admis-
sions due to VAP occurred in 38 hospitals during the 
study period (33% in university hospitals, 54% in central 
hospitals and 13% in regional hospitals). Mortality and 
cause of death data (follow- up ended in 31.12.2014) for 
the identified patients were obtained from nationwide 
and obligatory cause of death registry held by Statistics 
Finland. The comorbidities of the patients were described 
by Charlson comorbidity index (CCI). Annual admis-
sions rates (one admission per year) were estimated by 
using age- matched and gender- matched population data 
of mainland Finland from the study period (46 642 940 
person- years) obtained from Statistics Finland.
Statistical analysis
Scale variables are presented as mean±SD and categor-
ical variables are presented as counts or percentages with 
95% CIs when applicable. Gender differences in base-
line features were analysed using t- test or χ2 test. Count 
data were analysed by using negative binomial regression 
models. In the regression models of annual admission 
rate, the logarithm of population was used as an offset 
parameter.
All- cause mortality from first VAP admission was studied 
using Kaplan- Maier method and Cox regression. Dura-
tion of hospital admission was calculated as beginning 
days.
Results of regression analyses are given as rate ratios 
(RR) or HRs as appropriate. CCI was calculated according 
to previously used algorithm.12 Admission rates of admis-
sions (one admission per year) were standardised to 
WHO 2010 standard population with the use of a direct 
method as appropriate. P values <0.05 were considered 
statistically significant. Analyses were performed with the 
SAS system V.9.4.
Patient and public involvement
This study is based on a retrospective registry data and 
does not have direct involvement of patients or the public.
reSultS
Patient features
VAP was the primary cause for 1762 hospital admis-
sions (1570 individual patients, 59.7% male) during 
the study period. Demographic baseline characteristics 
of the hospitalised patients are shown in table 1. Mean 
age of all VAP patients was 65.7±12.0 years (range 18–98 
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Figure 1 Frequency of vasospastic angina pectoris admissions. Age- distribution of all patients (A) and by gender (from total 
number of patients) (B). Error bars represent upper limits of 95% CIs.
years) (figure 1A). Age distribution of VAP patients had 
similar patterns in both genders, although age- pattern 
was shifted towards older age in women (figure 1B) 
with female patients being marginally older compared 
with men (table 1). Comorbidity burden of patients was 
similar between genders (table 1). Coronary angiog-
raphy was performed in 56% admissions and was more 
common for men than for women, who were hospital-
ised for VAP (table 1). Majority of VAP patients had no 
detected coronary obstruction, but obstructive disease 
was more common in men than in women (table 1). 
Admission for vasospastic angina lasted on average 
for 4.3±3.7 (range 1–44 days) with no difference in 
duration of admission between genders. MI (I21.X) 
copyright.
 o
n
 M
arch 13, 2020 at University of Helsinki. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030768 on 3 November 2019. Downloaded from 
4 Pikkarainen E, et al. BMJ Open 2019;9:e030768. doi:10.1136/bmjopen-2019-030768
Open access 
Figure 2 Annual rate of vasospastic angina pectoris 
admission in general adult population. Admission rates (per 
100 000 person- years) by age. Error bars represent upper 
limits of 95% CIs.
Figure 3 Gender- associated admission rate ratio of 
vasospastic angina pectoris by age in general population. 
Ratio is calculated as men versus women and adjusted for 
background population and study year. Error bars represent 
95% CIs.
Figure 4 Trend for annual rate of vasospastic angina 
pectoris admissions in general adult population. Standardised 
to who standard population. Error bars represent 95% CIs.
was secondary or a tertiary diagnosis for 1.8% of VAP 
patients.
Annual admission rate
During the whole study period, the total standardised 
annual admission rate for VAP was 2.29 (95% CI 2.15 
to 2.43)/100 000 person- years (crude rate 3.45 (95% CI 
3.29 to 3.63)/100 000). Likelihood of VAP admission 
increased progressively from 40 to 70 years of age with 
highest rate (10.5/100 000) in patients aged 70–75 years 
(figure 2). Among women, the standardised overall rate 
for VAP hospital admission was 1.68 (95% CI 1.52 to 
1.86)/100 000 person- years (crude rate 2.71 (95% CI 1.52 
to 1.86)/100 000), whereas for men the standardised rate 
was 3.00 (95% CI 2.77 to 3.22)/100 000 (crude rate 4.25 
(95% CI 3.98 to 4.53)/100 000). In total Finnish adult 
population, men were 70% more likely to be admitted to 
hospital due to VAP (RR for admission rate 1.70; 95% CI 
1.39 to 2.08; p<0.0001) than women. Gender difference 
was similar between age groups (interaction p=0.201) 
(figure 3). Admission rate for VAP decreased notably 
during the study period (figure 4).
Mortality
Thirty- day all- cause mortality was 3.2%, 1- year mortality 
was 8.0% and 3- year mortality was 15.5% after admission 
for VAP (figure 5). One- year mortality was associated with 
increasing age, comorbidity burden and coronary artery 
status, but was similar between genders and study periods 
(table 2). Comparably, 3- year mortality was associated 
with increasing age, CCI- score and lack of detected coro-
nary artery obstruction but was similar between genders 
during study (table 3). Majority (71.2%) of all the deaths 
were due to cardiac causes with cardiac mortality of 5.8% 
at 1- year and 11.1% at 3- year follow- up. MI and ischaemic 
heart disease were most common underlying causes of 
death.
dISCuSSIOn
This nationwide study describes the occurrence of VAP 
admissions in Finnish general population. Men were 
70% more likely to be admitted for VAP compared 
with woman. All- cause mortality was 8.0% at 1 year and 
15.5% at 3 years. Mortality was associated with older age, 
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Figure 5 Cumulative all- cause mortality after vasospastic 
angina pectoris admission.
Table 2 Factors associated with 1- year all- cause mortality. Univariate and multivariate analysis
Variable
Mortality 
(%)
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Gender       0.795     0.311
  Male 7.82 Ref.           
  Female 8.19 1.05 0.73 to 1.50 0.795 0.83 0.57 to 1.19 0.311
Age (years)       <0.0001     <0.0001
  <50 2.16 Ref.     Ref.     
  50–59 0.85 0.4 0.08 to 2.00 0.267 0.4 0.08 to 1.97 0.259
  60–69 5.46 2.62 0.79 to 8.71 0.117 2.25 0.67 to 7.53 0.189
  70–79 10.26 5.03 1.56 to 16.19 0.007 4.15 1.28 to 13.45 0.018
  80− 24.26 13.12 4.09 to 42.06 <0.0001 9.95 3.06 to 32.33 0.0001
CCI       <0.0001     <0.0001
  0 4.18 Ref.     Ref.     
  1 7.82 1.88 1.15 to 3.07 0.011 1.47 0.90 to 2.42 0.127
  2 17.39 4.39 2.75 to 7.02 <0.0001 2.68 1.65 to 4.36 <0.0001
  ≥3 19.23 4.82 2.89 to 8.03 <0.0001 3.33 1.97 to 5.64 <0.0001
Coronary status       0.006     0.149
  Obstruction 4.55 Ref.     Ref.     
  No obstruction 8.36 1.87 1.12 to 3.14 0.017 1.69 0.99 to 2.87 0.05
  NAS 10.67 2.41 1.41 to 4.12 0.001 1.51 0.87 to 2.65 0.155
Study year       0.198     0.564
  2004–2006 7.26 Ref.     Ref.     
  2007–2010 7.62 1.05 0.70 to 1.56 0.821 0.99 0.66 to 1.49 0.97
  2010–2014 10.79 1.44 0.90 to 2.31 0.086 1.26 0.78 to 2.07 0.338
CCI, Charlson comorbidity index; NAS, Not otherwise specified.
comorbidities and non- obstructive or non- specific coro-
nary findings but it was similar between genders.
The diagnosis of vasospastic angina is characterised 
by spontaneous chest pains and drug or non- drug (ie, 
hyperventilation) induced spasm. The gold standard of 
coronary artery spasm testing involves the administra-
tion of a provocative stimulus during coronary angiog-
raphy.4 In our study population, coronary angiography 
was undertaken in 58% of men and in 53% of women 
hospitalised for VAP.
It is known from previous studies that coronary spasm 
may develop in sclerotic lesions of varying severity.3 5 
Even if no stenotic lesions are visible on coronary angi-
ography, intravascular ultrasound (IVUS) commonly 
reveals arteriosclerotic lesions in locations consistent with 
regions of coronary spasm.3 It has been shown that with 
optical coherence tomography (OCT), thrombus was 
seen in one- fourth of patients with vasospastic angina and 
luminal irregularity was observed in nearly two- thirds of 
the study patients.5 In the present study, atherosclerotic 
changes in coronary arteries were diagnosed in 33% of 
men and 21% of women.
We found the overall annual admission rate for 
VAP to be 2.3/100 000. This compares to previously 
detected admission rates of 93/100 000 for unstable 
angina pectoris,13 105/100 000 for ST- elevation MI14 
and 206/100 000 for non- ST- elevation MI15 in Finnish 
adult population. Volume of VAP admissions can thus be 
copyright.
 o
n
 M
arch 13, 2020 at University of Helsinki. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030768 on 3 November 2019. Downloaded from 
6 Pikkarainen E, et al. BMJ Open 2019;9:e030768. doi:10.1136/bmjopen-2019-030768
Open access 
Table 3 Factors associated with 3- year all- cause mortality. Univariate and multivariate analysis
Variable
Mortality 
(%)
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Gender       0.788     0.065
  Male 15.78 Ref.           
  Female 15.15 0.97 0.74 to 1.26 0.788 0.78 0.59 to 1.02 0.065
Age (years)       <0.0001     <0.0001
  <50 4.6 Ref.     Ref.     
  50–59 5.09 1.1 0.44 to 2.80 0.835 1.08 0.42 to 2.74 0.876
  60–69 10.27 2.35 1.00 to 5.53 0.05 2.05 0.87 to 4.84 0.102
  70–79 20.22 4.84 2.12 to 11.07 0.0002 4.13 1.80 to 9.48 0.0008
  80− 41.33 11.78 5.14 to 26.98 <0.0001 9 4.02 to 21.52 <0.0001
CCI       <0.0001     <0.0001
  0 9.65 Ref.     Ref.     
  1 14.57 1.57 1.11 to 2.23 0.01 1.25 0.88 to 1.78 0.208
  2 28.87 3.42 2.43 to 4.82 <0.0001 2.29 1.61 to 3.27 <0.0001
  ≥3 36.65 4.36 3.03 to 6.27 <0.0001 3.26 2.17 to 4.59 <0.0001
Coronary status       <0.0001     0.045
  Obstruction 10.08 Ref.     Ref.     
  No obstruction 15.15 1.56 1.09 to 2.24 0.016 1.51 1.05 to 2.19 0.028
  NAS 21.67 2.3 1.59 to 3.34 <0.0001 1.61 1.09 to 2.37 0.017
Study year       0.311     0.609
  2004–2006 15.26 Ref.     Ref.     
  2007–2010 14.76 0.96 0.73 to 1.28 0.796 0.8 0.68 to 1.21 0.511
  2010–2014 17.81 1.29 0.89 to 1.87 0.188 1.1 0.75 to 1.6 0.64
CCI, Charlson comorbidity index; NAS, Not otherwise specified.
estimated to be approximately 1% of the amount of acute 
coronary syndrome (ACS) admissions. Decreasing VAP 
admissions are however, likely to affect this ratio.
In Japan as well as in western countries vasospastic 
angina is more prevalent in males. The gender- difference 
diminishes after menopause and disappears at the age of 
80 in Japanese population.3 We found VAP to be 70% 
more common among men while gender- difference was 
not modified by age. VAP is known to cause significant 
morbidity to individuals affected.16 In Korean popula-
tion mortality was 2% at 2 years5 with similar prognosis 
in both genders.17 In a Japanese study population, the 
MI was 3% at 3 years.3 In western population the 3- year 
MI mortality has been reported to be 11%3 comparably 
to our results.
In Caucasian study population of VAP without signif-
icant atherosclerotic stenosis, the mortality was 24% at 
12- year follow- up with mostly non- cardiac deaths.11
We found 3- year mortality to be 15.5% and to be mostly 
cardiogenic. In an earlier study, the risk of death and MI 
was similar in male ST- segment elevation MI patients and 
VAP patients while VAP patients with non- significant coro-
nary stenosis seemed to have less complications and lower 
mortality.18
Our results suggest that the VAP might not be as benign 
disease as often thought. We can assume, that most the 
of patients with a diagnostic code of narrowing or occlu-
sive coronary artery findings, had a visible narrowing or 
occlusion in the coronary arteries and had been taken 
care of by intervention or medication for coronary 
artery decease in the well- functioning Finnish healthcare 
system. For rest of the study population, coronary angi-
ography did not reveal atherosclerotic changes, or the 
angiography was not performed during index admission. 
For comparison, in a Swedish register study, the 1- year 
mortality after admission for unstable angina pectoris was 
10% in age group 65–105.19 Interestingly, a Korean study 
found VAP patients presenting with ACS to have worse 
prognosis compared with VAP patients without presenta-
tion of ACS.9 One potential mechanism for VAP related 
mortality are vasospasm triggered arrythmias. In agree-
ment, previous studies have shown VAP patients with 
aborted sudden cardiac death to have worse prognosis 
than those without.16 20
In North America, vasospastic angina has become less 
frequent for unknown reasons, possibly relating to more 
widespread use of calcium antagonists.21 Up to 70% of 
patients with ACS presenting with typical ECG changes 
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and/or elevation of cardiac markers had culprit lesions, 
whereas the remaining 30% of ACS patients had no 
obstructive coronary artery lesions. Cardiologists in the 
USA do not perform spasm provocation tests routinely 
in patients with non- obstructive coronary artery disease 
with chest pain/discomfort in the cardiac catheterisa-
tion laboratory.21 Similarly, in our study, the occurrence 
of VAP admissions decreased notably during the study 
period. Underling reason for this change is unknown. In 
addition to true decrease in VAP, this finding may relate 
to increase in rates of Takotsubo cardiomyopathy diag-
noses22 and high- sensitive troponin assay usage increasing 
alternative diagnoses for VAP during the study period.
The present study has some limitation. A major limita-
tion is the retrospective nature of observational registry 
data without access to more detailed clinical or thera-
peutic data. Diagnoses were based on the treating physi-
cian’s clinical impression and this may not have fulfilled 
published diagnostic criteria. This may have affected 
the selected study population and the accuracy of the 
comorbidity data. In addition, because our data included 
only hospitalised patients, the results under- represents 
patients with low- risk features who may have been treated 
without being admitted to the hospital or who have not 
sought for help. Coronary angiography was performed 
only for 56% of VAP patients. Some of the coronary artery 
disease diagnoses might thus have been missed. Further-
more, the spasm provocation tests are seldomly used in 
Finland limiting the accuracy of VAP diagnoses.
In conclusion, our results suggest that men have higher 
risk for vasospastic angina causing admissions compared 
with women. Likelihood of vasospastic angina admission 
was highest in population aged 70–84 years. The 3- year 
mortality was 15.5% and was predicted by patients age 
and comorbidities, but also by non- obstructive vasospastic 
angina diagnosis. The cause of death was mostly cardiac 
at 1- year and 3- year follow- ups. These results may help 
characterise the inadequately known epidemiology of 
VAP in western countries.
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